Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 2
2005 4
2006 5
2007 5
2008 7
2009 8
2010 8
2011 7
2012 9
2013 14
2014 14
2015 13
2016 14
2017 11
2018 30
2019 24
2020 21
2021 14
2022 16
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Three-year outcomes of vascular endothelial growth factor inhibitors in naïve branch retinal vein occlusion: Fight Retinal Blindness!
Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. Alforja S, et al. Among authors: gillies mc. Ophthalmol Retina. 2024 Apr 17:S2468-6530(24)00189-1. doi: 10.1016/j.oret.2024.04.014. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38641007
Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry.
Garay-Aramburu G, Hunt A, Arruabarrena C, Mehta H, Invernizzi A, Gabrielle PH, Guillaumie T, Wolff B, Gillies MC, Zarranz-Ventura J. Garay-Aramburu G, et al. Among authors: gillies mc. Sci Rep. 2024 Mar 13;14(1):6122. doi: 10.1038/s41598-024-56581-6. Sci Rep. 2024. PMID: 38480837 Free PMC article.
Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration.
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, Arruabarrena C, Fernandez-Hortelano A, Figueroa MS, Abraldes M, Lavid de Los Mozos FJ, Zapata MA, Ruiz-Moreno JM, Broc-Iturralde L, Gonzalez-Guijarro J, Escobar-Barranco JJ, Gallego-Pinazo R, Parrado-Carrillo A, Dotti-Boada M, Alforja S, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J; Writing Committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group. Izquierdo-Serra J, et al. Among authors: gillies mc. Ophthalmol Retina. 2024 Apr;8(4):350-359. doi: 10.1016/j.oret.2023.10.022. Epub 2023 Nov 2. Ophthalmol Retina. 2024. PMID: 37924946
Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.
Debourdeau E, Medard R, Chamard C, Nguyen V, Gabrielle PH, Creuzot-Garcher C, Allieu S, Gillies MC, Barthelmes D, Daien V; Fight Retinal Blindness! Study Group. Debourdeau E, et al. Among authors: gillies mc. Ophthalmol Ther. 2023 Oct;12(5):2657-2670. doi: 10.1007/s40123-023-00758-1. Epub 2023 Jul 28. Ophthalmol Ther. 2023. PMID: 37505396 Free PMC article.
Opportunities and challenges for clinical registries.
Kandel H, Gillies MC, Watson SL. Kandel H, et al. Among authors: gillies mc. Clin Exp Ophthalmol. 2023 Aug;51(6):651-652. doi: 10.1111/ceo.14260. Epub 2023 May 28. Clin Exp Ophthalmol. 2023. PMID: 37246495 No abstract available.
206 results